These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 37848671)

  • 1. N6-methyladenosine reader protein IGF2BP1 suppresses CD8 + T cells-mediated tumor cytotoxicity and apoptosis in colon cancer.
    Peng Y; Zhang Z; Yang G; Dai Z; Cai X; Liu Z; Yun Q; Xu L
    Apoptosis; 2024 Apr; 29(3-4):331-343. PubMed ID: 37848671
    [TBL] [Abstract][Full Text] [Related]  

  • 2. N
    Tang B; Bi L; Xu Y; Cao L; Li X
    Mol Biotechnol; 2024 Oct; 66(10):2850-2859. PubMed ID: 37817028
    [TBL] [Abstract][Full Text] [Related]  

  • 3. N
    Wang Y; Jin P; Wang X
    Apoptosis; 2024 Feb; 29(1-2):142-153. PubMed ID: 37698736
    [TBL] [Abstract][Full Text] [Related]  

  • 4. N
    Liu Z; Wang T; She Y; Wu K; Gu S; Li L; Dong C; Chen C; Zhou Y
    Mol Cancer; 2021 Aug; 20(1):105. PubMed ID: 34416901
    [TBL] [Abstract][Full Text] [Related]  

  • 5. JNK Signaling Promotes Bladder Cancer Immune Escape by Regulating METTL3-Mediated m6A Modification of PD-L1 mRNA.
    Ni Z; Sun P; Zheng J; Wu M; Yang C; Cheng M; Yin M; Cui C; Wang G; Yuan L; Gao Q; Li Y
    Cancer Res; 2022 May; 82(9):1789-1802. PubMed ID: 35502544
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RNA N6-methyladenosine demethylase FTO regulates PD-L1 expression in colon cancer cells.
    Tsuruta N; Tsuchihashi K; Ohmura H; Yamaguchi K; Ito M; Ariyama H; Kusaba H; Akashi K; Baba E
    Biochem Biophys Res Commun; 2020 Sep; 530(1):235-239. PubMed ID: 32828292
    [TBL] [Abstract][Full Text] [Related]  

  • 7. circATAD2 mitigates CD8
    Zhang Z; Huo W; Li J
    Cancer Immunol Immunother; 2024 May; 73(7):130. PubMed ID: 38748254
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TRIM29 promotes antitumor immunity through enhancing IGF2BP1 ubiquitination and subsequent PD-L1 downregulation in gastric cancer.
    Jiang T; Xia Y; Li Y; Lu C; Lin J; Shen Y; Lv J; Xie L; Gu C; Xu Z; Wang L
    Cancer Lett; 2024 Jan; 581():216510. PubMed ID: 38029830
    [TBL] [Abstract][Full Text] [Related]  

  • 9. N
    Yu F; Feng Y; Wang Q; Sun J
    Cell Biochem Biophys; 2024 Sep; 82(3):2321-2331. PubMed ID: 38872051
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting inhibition of prognosis-related lipid metabolism genes including CYP19A1 enhances immunotherapeutic response in colon cancer.
    Liu L; Mo M; Chen X; Chao D; Zhang Y; Chen X; Wang Y; Zhang N; He N; Yuan X; Chen H; Yang J
    J Exp Clin Cancer Res; 2023 Apr; 42(1):85. PubMed ID: 37055842
    [TBL] [Abstract][Full Text] [Related]  

  • 11. METTL3/IGF2BP3 axis inhibits tumor immune surveillance by upregulating N
    Wan W; Ao X; Chen Q; Yu Y; Ao L; Xing W; Guo W; Wu X; Pu C; Hu X; Li Z; Yao M; Luo D; Xu X
    Mol Cancer; 2022 Feb; 21(1):60. PubMed ID: 35197058
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PLGA Nanoparticles Codelivering siRNAs against Programmed Cell Death Protein-1 and Its Ligand Gene for Suppression of Colon Tumor Growth.
    Kwak SY; Lee S; Han HD; Chang S; Kim KP; Ahn HJ
    Mol Pharm; 2019 Dec; 16(12):4940-4953. PubMed ID: 31651174
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ANXA1-derived peptide for targeting PD-L1 degradation inhibits tumor immune evasion in multiple cancers.
    Yu ZZ; Liu YY; Zhu W; Xiao D; Huang W; Lu SS; Yi H; Zeng T; Feng XP; Yuan L; Qiu JY; Wu D; Wen Q; Zhou JH; Zhuang W; Xiao ZQ
    J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 37001908
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of Novel PD-L1 Small-Molecular Inhibitors with Potent
    Liu L; Zhang H; Hou J; Zhang Y; Wang L; Wang S; Yao Z; Xie T; Wen X; Xu Q; Dai L; Feng Z; Zhang P; Wu Y; Sun H; Liu J; Yuan H
    J Med Chem; 2024 Mar; 67(6):4977-4997. PubMed ID: 38465588
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tristetraprolin Overexpression in Gastric Cancer Cells Suppresses PD-L1 Expression and Inhibits Tumor Progression by Enhancing Antitumor Immunity.
    Guo J; Qu H; Shan T; Chen Y; Chen Y; Xia J
    Mol Cells; 2018 Jul; 41(7):653-664. PubMed ID: 29936792
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular mechanism of lncRNA SNHG12 in immune escape of non-small cell lung cancer through the HuR/PD-L1/USP8 axis.
    Huang Y; Xia L; Tan X; Zhang J; Zeng W; Tan B; Yu X; Fang W; Yang Z
    Cell Mol Biol Lett; 2022 Jun; 27(1):43. PubMed ID: 35658874
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LncRNA MALAT1 promotes tumorigenesis and immune escape of diffuse large B cell lymphoma by sponging miR-195.
    Wang QM; Lian GY; Song Y; Huang YF; Gong Y
    Life Sci; 2019 Aug; 231():116335. PubMed ID: 30898647
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PD-1/PD-L1 blockade rescue exhausted CD8+ T cells in gastrointestinal stromal tumours via the PI3K/Akt/mTOR signalling pathway.
    Zhao R; Song Y; Wang Y; Huang Y; Li Z; Cui Y; Yi M; Xia L; Zhuang W; Wu X; Zhou Y
    Cell Prolif; 2019 May; 52(3):e12571. PubMed ID: 30714229
    [TBL] [Abstract][Full Text] [Related]  

  • 19. LRPPRC facilitates tumor progression and immune evasion through upregulation of m
    Wang H; Tang A; Cui Y; Gong H; Li H
    Front Immunol; 2023; 14():1144774. PubMed ID: 37063837
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Programmed Death Ligand 1 Indicates Pre-Existing Adaptive Immune Response by Tumor-Infiltrating CD8
    Li YM; Yu JM; Liu ZY; Yang HJ; Tang J; Chen ZN
    Int J Mol Sci; 2019 Oct; 20(20):. PubMed ID: 31627272
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.